Navigation Links
Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011
Date:10/21/2011

MISSISSAUGA, Ontario, Oct. 21, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Thursday, November 3, 2011 at 10:00 a.m. ET (7:00 a.m. PT) to discuss results for the 2011 third quarter.

The dial-in number to participate on this call is (877) 295-5743, confirmation code 18668216.  International callers should dial (973) 200-3961, confirmation code 18668216. A replay will be available approximately two hours following the conclusion of the conference call to Thursday, November 10, 2011, and can be accessed by dialing (855) 859-2056 or (404) 537-3406, confirmation code 18668216.

The webcast and slide presentation will be hosted in the investor relations section of its corporate Web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant can be found at www.valeant.com.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada
2. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
3. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
4. Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa
5. Valeant Pharmaceuticals to Present at Industry Conferences
6. Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program
7. Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid
8. Valeant Pharmaceuticals Completes Acquisition of Sanitas Group
9. Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeants Board of Directors
10. Valeant Pharmaceuticals Reports 2011 Second Quarter Financial Results
11. Valeant Pharmaceuticals Announces Approval of Sublinox® in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ENGLEWOOD, Colo. , March 22, 2017 /PRNewswire/ ... leader in the development of Ampion™, a low ... anti-inflammatory properties, today announced that it is re-issuing its ... 2017 to incorporate certain disclosures that are required ... and 610(b). Included below are these additional disclosures along ...
(Date:3/22/2017)... Inc. today announced the appointment of Martyn Coombs as ... of ImaginAb, said "At ImaginAb we have exciting science and technology. ... our business, particularly in commercializing and making step changes in the ... realize our potential." ... Mr. Coombs is a recognized industry leader in nuclear medicine and ...
(Date:3/22/2017)... 22. März 2017   VWR ... tätige Anbieter von Produkten und Dienstleistungen für ... von EPL Archives Inc. bekannt, eines internationalen ... im kompletten Zyklus regulierter Forschung, Entwicklung und ... Speicherung von Dokumenten und Zusatzdienstleistungen zur Seite ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... The Rett Syndrome Research Trust ... disorder that afflicts 350,000 individuals worldwide. Rett Syndrome is caused by alterations ... strikes females. Following a normal infancy, Rett Syndrome takes effect in toddlerhood ...
(Date:3/22/2017)... ... , ... Last year, 43 million gallons of surplus milk was reportedly dumped ... excess dairy can be caused by several factors, one pharmaceutical company CEO suggests high ... digest lactose, a sugar found in milk and milk products. It is ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... planning, and related services to communities across eastern Texas, is announcing a charity ... providing meals to hungry children and adults. , Consistently a top-rated nonprofit ...
(Date:3/22/2017)... ... March 22, 2017 , ... Martin J. Mitchell Insurance, ... to communities throughout central Ohio, is initiating a charity drive to raise support ... of Defense and the Veteran's Brain Injury Center conclude that more than one ...
(Date:3/22/2017)... ... ... NYC Chiropractor Dr. Steven Shoshany recently helped host a seminar at his cutting ... and focused on a new protocol for treating pain. Dr. Shoshany is among the ... furthermore the first seminar in the country was hosted at his Integrated Chiropractic Practice. ...
Breaking Medicine News(10 mins):